Monzó Gallo, PatriciaChumbita, MarianaLopera, CarlosAiello, Tommaso F.Peyrony, OliverBodro, MartaHerrera, SabinaSempere, AbiuFernández Pittol, MarianaCuesta, GenovevaSimó, SílviaBenegas, MarianaFortuny Guasch, ClaudiaMensa, JosepSoriano, ÀlexPuerta-Alcalde, PedroMarco, FrancescGarcia Vidal, CarolinaFUNGIclinic group2024-01-242024-03-012023-03-011460-2709https://hdl.handle.net/2445/206270We aimed to describe the current epidemiology of both hosts with invasive fungal infections (IFI) and causative fungi. And detail outcomes of these infections at 12 weeks in a real-life cohort of hospitalized patients. The study was retrospective and observational to describe IFI diagnosed in a tertiary hospital (February 2017 - December 2021). We included all consecutive patients meeting criteria for proven or probable IFI according to EORTC-MSG and other criteria. A total of 367 IFI were diagnosed. 11.7% were breakthrough infections, and 56.4% were diagnosed in the intensive care unit (ICU). Corticosteroid use (41.4%) and prior viral infection (31.3%) were the most common risk factors for IFI. Lymphoma and pneumocystis pneumonia were the most common baseline and fungal diseases. Only 12% of IFI occurred in patients with neutropenia. Fungal cultures were the most important diagnostic tests (85.8%). The most frequent IFI were candidemia (42.2%) and invasive aspergillosis (26.7%). Azole-resistant candida strains and non-fumigatus aspergillus infection represented 36.1% and 44.5% of the cases, respectively. Pneumocystosis (16.9%), cryptococcosis (4.6%) and mucormycosis (2.7%) were also frequent, as well as mixed infections (3.4%). Rare fungi accounted for 9.5% of infections. Overall IFI mortality at 12 weeks was 32.2%; higher rates were observed for Mucorales (55.6%), Fusarium (50%) and mixed infections (60%). We documented emerging changes in both hosts and real-life IFI epidemiology. Physicians should be aware of these changes to suspect infections and be aggressive in diagnoses and treatments. Currently, outcomes for such clinical scenarios remain extremely poor.© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.application/pdfeng(c) Monzo Gallo, Patricia, 2023Aspergil·losiPneumòniaAspergillosisPneumoniainfo:eu-repo/semantics/article2024-01-18info:eu-repo/semantics/openAccess934354636861308